THE RELATIONSHIP BETWEEN DEBRISOQUINE OXIDATION PHENOTYPE AND THE PHARMACOKINETICS OF CHLORPROPAMIDE

被引:2
|
作者
KALLIO, J
HUUPPONEN, R
PYYKKO, K
机构
[1] Departments of Pharmacology and Clinical Pharmacology, University of Turku
关键词
Chlorpropamide; Debrisoquine phenotype; Metabolism; Pharmacogenetics; Pharmacokinetics;
D O I
10.1007/BF02657068
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pharmacokinetics and urinary metabolite pattern of a single oral dose of chlorpropamide 250 mg have been studied in 6 extensive and 5 poor metabolizers of debrisoquine. Ammonium chloride was given orally to acidify the urine in order to make elimination of the parent drug dependent on metabolism alone. The concentration profile in serum and the pharmacokinetic parameters of the parent drug were similar in both groups. However, the ratio in urine of unchanged chlorpropamide to its hydroxylated metabolites was higher in poor than in extensive metabolizers. © 1990 Springer-Verlag.
引用
收藏
页码:93 / 95
页数:3
相关论文
共 50 条
  • [31] DEBRISOQUINE PHENOTYPE AND THE PHARMACOKINETICS AND BETA-2 RECEPTOR PHARMACODYNAMICS OF METOPROLOL AND ITS ENANTIOMERS
    JONKERS, RE
    KOOPMANS, RP
    PORTIER, EJG
    VANBOXTEL, CJ
    JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 1991, 256 (03): : 959 - 966
  • [32] Determination of debrisoquine oxidation phenotype in healthy volunteers during phase I trials
    Girard, I
    Ferry, S
    Nony, P
    Boissel, JP
    THERAPIE, 1996, 51 (02): : 191 - 192
  • [33] DEBRISOQUINE PHENOTYPE AND GENOTYPE IN CHINESE
    LEE, EJD
    MOOCHHALA, SM
    LANCET, 1989, 2 (8678-9): : 1534 - 1535
  • [35] RELATIONSHIP BETWEEN THE DEBRISOQUINE HYDROXYLASE POLYMORPHISM AND CANCER SUSCEPTIBILITY
    WOLF, CR
    SMITH, CAD
    GOUGH, AC
    MOSS, JE
    VALLIS, KA
    HOWARD, G
    CAREY, FJ
    MILLS, K
    MCNEE, W
    CARMICHAEL, J
    SPURR, NK
    CARCINOGENESIS, 1992, 13 (06) : 1035 - 1038
  • [36] ACETYLATION AND OXIDATION PATHWAYS IN SYSTEMIC LUPUS-ERYTHEMATOSUS - INCREASED FREQUENCY OF THE DEFICIENT DEBRISOQUINE OXIDATION PHENOTYPE
    BAER, AN
    PINCUS, T
    DOYLE, DR
    WILKINSON, GR
    WOOSLEY, RL
    CLINICAL RESEARCH, 1985, 33 (03): : A786 - A786
  • [37] DEBRISOQUINE OXIDATION PHENOTYPE AND PLASMA KINETICS OF INDORAMIN AND ITS METABOLITE 6-HYDROXYINDORAMIN
    PIERCE, DM
    SMITH, SE
    FRANKLIN, RA
    ACTA PHARMACOLOGICA ET TOXICOLOGICA, 1986, 59 : 117 - 117
  • [38] EXERCISE PERFORMANCE RELATED TO DEBRISOQUINE OXIDATION PHENOTYPE AFTER SINGLE DOSES OF METOPROLOL AND ATENOLOL
    LEWIS, RV
    JACKSON, PR
    RAMSAY, LE
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1988, 26 (05) : P630 - P631
  • [39] STEREOSELECTIVITY AND REGIOSELECTIVITY OF HEPATIC OXIDATION IN MAN - EFFECT OF THE DEBRISOQUINE SPARTEINE PHENOTYPE ON BUFURALOL HYDROXYLATION
    DAYER, P
    LEEMANN, T
    KUPFER, A
    KRONBACH, T
    MEYER, UA
    EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 1986, 31 (03) : 313 - 318
  • [40] Relationship between Type A and B personality and debrisoquine hydroxylation capacity
    Gan, SH
    Ismail, R
    Wan Adnan, WA
    Zulmi, W
    Kumaraswamy, N
    Larmie, ET
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2004, 57 (06) : 785 - 789